MCM
GLUE icon

MAI Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

MAI Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.73K Buy
227
+194
+588% +$3.71K ﹤0.01% 3655
2025
Q4 		$518 Buy
+33
New +$445 ﹤0.01% 3816

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MAI Capital Management's GLUE Position: Q1 2026 in Review

MAI Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 588% in Q1 2026, buying an estimated $3.71K and bringing the position to 227 shares worth $3.73K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

MAI Capital Management first reported a position in GLUE in Q4 2025 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • MAI Capital Management held 227 shares of Monte Rosa Therapeutics worth $3.73K as of Q1 2026.
  • MAI Capital Management bought 194 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.71K.
  • Monte Rosa Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3655 holding.
  • MAI Capital Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.